Do exclusive licenses block competition in the gene testing market ?

There's some buzz on Gene patents and licensing: Case studies prepared for the Secretary’s Advisory Committee on Genetics, Health, and Society by Robert Cook-Deegan, MD, and Christopher Heaney, BA, with abstract:

Researchers at the Center for Public Genomics at Duke
University analyzed how patenting and licensing affect clinical access
to genetic testing in the United States. The research was requested by
the Secretary’s Advisory Committee on Genetics, Health, and Society. [(SACGHS) ]
Conditions studied were breast and ovarian cancers, colon cancers,
Alzheimer disease, cystic fibrosis, hearing loss, hereditary hemochro-
matosis, long QT syndrome, spinocerebellar ataxia, Tay-Sachs disease,
and Canavan disease.In January 2007, the graduate and professional student cap-
stone section of Duke’s Health Policy Certificate program made
the task force its client. Students enrolled in Professor Christo-
pher Conover’s course were joined by Dr. Subhashini Chan-
drasekharan of the CpG, Julia Carbone, a LLM student at Duke
Law, and Dr. Robert Cook-Deegan.

Separately,

Anthony D. So et al., Is Bayh-Dole Good for Developing Countries? Lessons from the US Experience, 6 Plos Biol 2078, 2081 (2008), available at

http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.0060262

http://www.dukenews.duke.edu/2010/04/genepatent.html

And from IPBiz

http://ipbiz.blogspot.com/2008/08/rais-wrong-on-reform.html

http://ipbiz.blogspot.com/2006/11/ksr-can-one-have-settled-expectation.html